Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

• Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophrenia
• Sosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties

Ingelheim, Germany, Tokyo, Japan and Cambridge, UK, 11 March 2024 – Today, Boehringer Ingelheim and Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) announced they have entered a global collaboration and exclusive option-to-license agreement. At the center is a joint mission to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, a novel G protein-coupled receptor (GPCR) target, with the intent to improve patient outcomes by simultaneously addressing positive, negative, and cognitive symptoms of schizophrenia^1,2,3.

Schizophrenia is a serious condition that affects about 1 in 100 people worldwide⁴. It is characterized by three clusters of symptoms^5,6:

• ‘Positive’ symptoms – such as psychosis, delusions and hallucinations
• ‘Negative’ symptoms – such as social withdrawal and apathy
• Cognitive symptoms – such as attention, planning and memory deficits

The impact of these symptoms on people’s ability to cope with normal day-to-day life is significant and the related burden on carers and society at large is substantial, especially since the age of onset of the disease is typically in the 20s⁷. While ‘positive’ symptoms can be stabilized with antipsychotics, some of which can have side effects, there are currently no approved medicines for ‘negative’ or cognitive symptoms.

The development of a new schizophrenia treatment targeting GPR52 has the potential to address all three aspects of schizophrenia^1,2 providing a novel precision treatment. This is based on the location of the receptor in the two areas of the brain that drive the positive (the striatum) and the negative and cognitive symptoms (the prefrontal cortex). The GPR52 agonism calms the striatum while boosting frontal cortical function, which achieves further precision in treatment⁸.